Expression of Ki67 according to treatment arm and ER status.
Summary of invasive breast cancer occurrence in tamoxifen and placebo arms in the BCPT by October 1, 2010, for all and patients with ER+ tumors during and after the treatment period
Major demographics of the IHC sample set
↵aOthers – unknown, moderate, poor, well, not assessable.
Comparison of biomarker expression between placebo and tamoxifen groups in overall follow-up period
↵aP value relates to the difference between PgR+ and PgR− among the ER+ by χ2 test.
Comparison of biomarker expression between placebo and tamoxifen groups in on-treatment and posttreatment follow-up periods
Sign up for alerts
Thank you for sharing this Cancer Prevention Research article.
NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.